We are delighted to share some exciting news: P4 Therapeutics has received public funding by the Austrian Research Promotion Agency (FFG).
2020 has been a rollercoaster so far, and this not only because of COVID-19. Newest developments in Albuplatin history truly led to a shift in focus - and contemporaneously revealed even more exciting opportunities.
Being accompanied by the FFG through the General Programme, we are excited to enter this new chapter with a strong partner.
Our family grows!
A warm welcome to our newest team member Regina Weinmüllner, PhD (Biotechnology; University of Natural Resources and Life Sciences, Vienna). Regina has been working at the interface between university and industry for many years. Together we will boost the Albuplatin development to the next level.
We did it again
No doubt, these are challenging times – for all of us! Hence, it is with added pleasure to announce that Albuplatin has been nominated for the Rudolf Sallinger Fonds Science&Business Award 2020.
P4 Therapeutics has entered into an exclusive license agreement with a pharmaceutical company. The two companies will unite their expertise in order to further develop Albuplatin for use in clinical trials - and beyond.
Christian Kowol vom Institut für Anorganische Chemie der Fakultät für Chemie und Petra Heffeter vom Institut für Krebsforschung der Medizinischen Universität Wien erhielten eine aws PreSeed Förderung für die Entwicklung ihres neuen Wirkstoffes Albuplatin. Das Projekt wird künftig unter Leitung von Nadine S. Sommerfeld durchgeführt.